Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

OBJECTIVES: The aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, Fleischmann, Roy, Furst, Daniel, Janssen, Namieta, Carter, John, Dasgupta, Bhaskar, Bryson, Judy, Duncan, Benjamin, Zhu, Wei, Pitzalis, Costantino, Durez, Patrick, Kretsos, Kosmas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/
https://www.ncbi.nlm.nih.gov/pubmed/24641941
http://dx.doi.org/10.1136/annrheumdis-2013-204760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/
https://www.ncbi.nlm.nih.gov/pubmed/24641941
http://dx.doi.org/10.1136/annrheumdis-2013-204760

Ejemplares similares